Identification of Novel Hits of the NSD1 SET Domain by NMR Fragment-Based Screening

doi:10.11938/cjmr20182696

Abstract

Abstract: Nuclear receptor binding SET domain protein 1 (NSD1), which is a family member of histone methyltransferases, functions to methylate histone H3 on lysine 36 (H3K36). NSD1-related abnormalities are the major cause of Sotos syndrome, and also known to be associated with other human diseases. Inhibitors targeting histone methyltransferases DOT1L and EZH2 have been reported recently. However, no chemical probes targeting NSD1 have been found so far. Here, we identified three hits targeting the NSD1 SET domain using ligand-observed nuclear magnetic resonance (NMR) fragment-based screening. The binding affinities of the hit compounds to the NSD1 SET domain were determined by dose-dependent chemical shift perturbation analysis. Furthermore, the potential binding modes of the hit compounds to NSD1 were obtained by molecular docking. The hit compound 1 was found to bind to the binding pocket of S-adenosylmethionine (SAM), an endogenous ligand of the protein, in the NSD1 SET domain. The study provided valuable information for further structure-guided hit-to-lead evolution towards the potent and specific inhibitors of the NSD1 SET domain.

Key words: NSD1 SET domain, NMR fragment-based screening, chemical shift perturbation, molecular docking

CLC Number:

O482.53

TANG Heng, Gilbert NSHOGOZA, LIU Ming-qing, LIU Ya-qian, RUAN Ke, MA Rong-sheng, GAO Jia. Identification of Novel Hits of the NSD1 SET Domain by NMR Fragment-Based Screening[J]. Chinese Journal of Magnetic Resonance, 2019, 36(2): 148-154.

References

[1] BAYLIN S B, JONES P A. A decade of exploring the cancer epigenome-biological and translational implications[J]. Nat Rev Cancer, 2011, 11(10):726-734.
[2] COLE P A. Chemical probes for histone-modifying enzymes[J]. Nat Chem Biol, 2008, 4(10):590-597.
[3] HAN J Y, LEE I G, JANG W, et al. Identification of a novel de novo nonsense mutation of the NSD1 gene in monozygotic twins discordant for Sotos syndrome[J]. Clin Chim Acta, 2017, 470:31-35.
[4] BERDASCO M, ROPERO S, SETIEN F, et al. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma[J]. Proc Natl Acad Sci U S A, 2009, 106(51):21830-21835.
[5] LU T, JACKSON M W, WANG B L, et al. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65[J]. Proc Natl Acad Sci U S A. 107(1):46-51.
[6] PERI S, IZUMCHENKO E, SCHUBERT A D, et al. NSD1-and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis[J]. Nat Commun. 2017, 8(1):1772.
[7] SHIBA N, ICHIKAWA H, TAKI T, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia[J]. Genes Chromosomes Cancer, 2013, 52(7):683-693.
[8] QIAO Q, LI Y, CHEN Z, et al. The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation[J]. J Biol Chem, 2011, 286(10):8361-8368.
[9] SU X P, ZHANG J P, MOUAWAD R, et al. NSD1 inactivation and SETD2 mutation drive a convergence toward loss of function of H3K36 writers in clear cell renal cell carcinomas[J]. Cancer Res, 2017, 77(18):4835-4845.
[10] VISSER R, LANDMAN E B, GOEMAN J, et al. Sotos syndrome is associated with deregulation of the MAPK/ERK-signaling pathway[J]. PLoS One, 2012, 7(11):e49229.
[11] WANG G G, CAI L, PASILLAS M P, et al. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis[J]. Nat Cell Biol, 2007, 9(7):804-812.
[12] TATTON-BROWN K, RAHMAN N. The NSD1 and EZH2 overgrowth genes, similarities and differences[J]. Am J Med Genet C Semin Med Genet, 2013, 163C(2):86-91.
[13] CHANG Y Q, ZHANG X, HORTON J R, et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294[J]. Nat Struct Mol Biol, 2009, 16(3):312-317.
[14] YAO Y, CHEN P H, DIAO J S, et al. Selective inhibitors of histone methyltransferase DOT1L:design, synthesis, and crystallographic studies[J]. J Am Chem Soc, 2011, 133(42):16746-16749.
[15] MCCABE M T, OTT H M, GANJI G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations[J]. Nature, 2012, 492(7427):108-112.
[16] ZHANG X Q, SONG F B, KUO G H, et al. Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors[J]. Bioorg Med Chem Lett, 2011, 21(16):4762-4767.
[17] MA R S, WANG P C, WU J H, et al. Process of fragment-based lead discovery-A perspective from NMR[J]. Molecules, 2016, 21(7):E854.
[18] WHITTAKER M. Picking up the pieces with FBDD or FADD:invest early for future success[J]. Drug Discov Today, 2009, 14(13/14):623-624.
[19] GAO J, MA R S, WANG W, et al. Automated NMR fragment based screening identified a novel interface blocker to the LARG/RhoA complex[J]. PLoS One, 2014, 9(2):e88098.
[20] LIU J Y, ZHANG S Y, LIU M Q, et al. Structural plasticity of the TDRD3 Tudor domain probed by a fragment screening hit[J]. FEBS J, 2018, 285(11):2091-2103.
[21] GAO J, LIANG E, MA R S, et al. Fluorine pseudocontact shifts used for characterizing the protein-ligand interaction mode in the limit of NMR intermediate exchange[J]. Angew Chem Int Ed Engl, 2017, 56(42):12982-12986.
[22] XU D F, LI B, GAO J, et al. Ligand proton pseudocontact shifts determined from paramagnetic relaxation dispersion in the limit of NMR intermediate exchange[J]. J Phys Chem Lett, 2018, 9(12):3361-3367.
[23] LIU J Y, GAO J, LI F D, et al. NMR characterization of weak interactions between RhoGDI2 and fragment screening hits[J]. Biochim Biophys Acta Gen Subj, 2017, 1861(1 Pt A):3061-3070.
[24] WILLIAMSON M P. Using chemical shift perturbation to characterise ligand binding[J]. Prog Nucl Magn Reson Spectrosc, 2013, 73:1-16.